All News

The FDA has granted Fast Track designation to BMS-986446, an anti-microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.

Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.

The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.

Measles vaccine coverage must reach 93% to maintain herd immunity but in 1 postelimination outbreak, the level reached only 80% in school-aged children.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

The annual meeting of the American Academy of Family Physicians is a unique chance to choose continuing education on just about any topic a family physician could imagine.

Review FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for UTIs, acute pain, migraine, diabetes, and more.

The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.

Vaccines for respiratory syncytial virus were found both safe and effective across 100,000 participants and, critically, for older adults and for infants.

Your daily dose of the clinical news you may have missed.

Adult vaccine-preventable diseases cost $26.5B annually in the US. See key gaps, barriers, and strategies primary care physicians can use to boost immunization.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

The approval is based on phase 3 trials showing durable IGF-1 control, symptom relief, and a favorable safety profile among adults with acromegaly.

Your daily dose of the clinical news you may have missed.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

Moore, in addition to her past work with ACIP, has deep roots in public health and advocacy, vaccine program implementation, and immunization education.

Missing a first screening mammogram was associated with a 53% greater risk of stage III breast cancer and a 40% higher risk of mortality from the disease.